BioTech company founder and CEO Bryan Johnson has been spending millions to reduce his age via sophisticated technology. His biotech company is running a project named ‘BluePrint’ that aims to alter the epigenetic constitution of humans, for which Johnson is also a part of the trials.
Nearly five years after unveiling the first clinical data for its BCMA-targeted CAR-T therapy, Legend Biotech has transitioned into a commercial company with an FDA approval for Carvykti and Johnso